MycoMed Technologies I Products to Prevent Infection

SBIR Phase I

//SBIR Phase I

SBIR Phase I

Feb 2015

Information sourced from SBIR Source:

SBIR Phase I Award

The Federal Small Business Innovation Research (SBIR) drives the creation of new businesses and development of wide-ranging technologies; competitive R&D funding available under this program is intended exclusively for small high-tech companies with a goal of commercialization of innovative technologies in diverse fields, from healthcare to energy to defence.

MycoMed Technologies LLC received a $238,000 SBIR Phase I grant from the National Science Foundation (NSF) for the period of 07/01/2015 – 06/30/2016, to enable the development of an immunoassay lateral flow-based device (LFD) using novel antibodies capable of detecting Aspergillus antigen in urine of patients of aspergillosis.

By | 2017-10-02T16:32:43+00:00 February 1st, 2015|